Share Prices & Company Research

Market News

21 Dec 2021 | 07:28

GlaxoSmithKline's ViiV Healthcare receives FDA approval for Apretude

(Sharecast News) - Pharmaceutical giant GlaxoSmithKline said on Tuesday that ViiV Healthcare, its majority-owned subsidiary, had received approval from the Food and Drug Administration for Apretude, a long-acting injectable pre-exposure prophylaxis option that reduces the risk of sexually acquired HIV-1. GlaxoSmithKline, which owns ViiV with Pfizer and Shionogi, stated the long-acting injectable had been approved for use in adults and adolescents weighing at least 35.0kg and were at risk of sexually acquiring HIV and who had turned in a negative HIV-1 test prior to initiation.

The FTSE 100-listed firm highlighted that the medicine had been studied in men who had sex with men, as well as women and transgender women who had sex with men, who it said were at an increased risk of sexually acquiring HIV.

Viiv's studies also showed that when given as few as six times per year, Apretude had demonstrated "superior efficacy" to a daily oral PrEP option in reducing the risk of HIV acquisition.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 17th May 2022
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.